Endometrial cancer trials in France

In France 47 Also abroad 405

47 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Besançon, Levallois-Perret, Marseille, Neuilly, Paris
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 2Taking people
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI
Where
Angers, Avignon Cedex 9, Besancon Cedex, Bordeaux, Brest, Caen Cedex 5, Clermont-Ferrand, Creteil, Dijon, Lille Cedex, Lyon, Marseille, Montivilliers, Nantes, Paris, Paris Cedex 12, Pessac, Poitiers, Reims, Reims Cedex, Rennes Cedex, Rouen Cedex, St Herblain, Strasbourg, Strasbourg Cedex 2, Suresnes, Toulouse Cedex 9, Vandouvre Les Nancy, Villejuif
Age
18 years and over
People
120
Run by
Unicancer
See details and how to join2023-505298-34-00
Phase 2Taking people
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Where
Caen Cedex 5, Lyon, Saint-Herblain Cedex, Villejuif
Age
18 years and over
People
350 worldwide
Run by
Acrivon Therapeutics
See details and how to joinNCT05548296 · EU 2025-524542-10-00
Phase 1Taking people
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Where
Marseille, Villejuif
Age
18 years and over
People
187 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07306559 · EU 2025-522913-45-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bordeaux, Lille, Lyon, Nantes, Strasbourg, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Villejuif
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
Where
Angers, Bayonne, Bordeaux, Brest, Clermont-Ferrand, Dijon, Grenoble, Montpellier Cedex 5, Nancy, Orleans Cedex 2, Reims, Strasbourg Cedex 2, Suresnes
Age
18 years and over
People
290 worldwide
Run by
Genmab A/S
See details and how to join2024-519818-31-01
Phase 3Taking people
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Where
Avignon Cedex 9, Besancon Cedex, Bordeaux, Chambray-lès-Tours, Cholet, Créteil, Grenoble, Lille, Limoges, Lyon, Nantes Cedex 2, Nimes Cedex 9, Paris, Plerin, Rennes Cedex
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Bordeaux, Paris, Villejuif
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 2Taking people
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Where
Lille, Nancy, Nice, Pierre-Bénite, Plérin, Toulouse
Age
18 years and over
People
270 worldwide
Run by
Corcept Therapeutics
See details and how to joinNCT06906341
Phase 1/2Taking people
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Where
Bordeaux, Lyon, Marseille, Nice Cedex 2, Toulouse, Villejuif
Age
18 years and over
People
880 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Where
Bayonne, Caen Cedex 5, Lille, Lyon, Marseille, Nice Cedex 2, Paris, St Herblain, Strasbourg, Villejuif
Age
18 years and over
People
182 worldwide
Run by
Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00
Phase 2Taking people
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
Where
Bordeaux, Caen Cedex 5, Clermont-Ferrand, Dijon, Marseille, Paris, Pierre-Bénite, Poitiers
Age
18 years and over
People
101 worldwide
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
See details and how to joinNCT05642780 · EU 2022-502654-14-00
Phase 2Taking people
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Where
Bordeaux, Lyon, Paris, Villejuif
Age
18 years and over
People
900
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07303387
No phaseTaking people
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Where
Toulouse
People
212 worldwide
Run by
Mayo Clinic
See details and how to joinNCT06689956
Phase 3Taking people
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Where
Albi, Angers, Besançon, Carcassonne, Dijon, Grenoble, Limoges, Lyon, Marseille, Nice, Paris, Saint-Herblain, Strasbourg, Villejuif
Age
18 years and over
People
554
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT06712472
Phase 2Taking people
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Where
Angers, Beauvais, Bordeaux, Brest, Clermont Ferrand Cedex1, Dijon, Lyon, Marseille, Nice Cedex 2, Paris, Poitiers, Reims, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
105
Run by
UNICANCER
See details and how to joinNCT07192068 · EU 2025-522169-31-00
Phase 2Taking people
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors.
Where
Bordeaux, Lyon, Paris, Villejuif
Age
18 years and over
People
600
Run by
Institut Gustave Roussy
See details and how to join2024-519788-16-00
Phase 2Taking people
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Where
Angers, Avignon, Besançon, Brest, Caen, Clermont-Ferrand, Créteil, Dijon, Lyon, Marseille, Nancy, Paris, Pessac, Poitiers, Reims, Rennes, Rouen, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
120
Run by
UNICANCER
See details and how to joinNCT06333314
No phaseTaking people
Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer.
Where
Lille, Limoges, Paris, Pierre-Bénite, Plérin, Rennes, Rouen, Saint-Etienne, Strasbourg, Tours
Age
18 years and over
People
1,680
Run by
Rennes University Hospital
See details and how to joinNCT06348719
No phaseTaking people
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Where
Caen
Age
18 years and over
People
16
Run by
Centre Francois Baclesse
See details and how to joinNCT06603506
No phaseTaking people
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Where
Bron, Lyon, Pierre-Bénite
Age
18 years and over
People
410
Run by
Hospices Civils de Lyon
See details and how to joinNCT03787056